In Brief: Medical Developments International, Ventracor, Anadis, Ozgen, GlaxoSmithKline
Thursday, 14 July, 2005
Chris Weaver has resigned as Medical Developments Internationa (ASX:MVP) managing director and CEO to take up an executive management position with a bank. Current CFO Jeremy Payling will act as interim CEO while the company searches for a new CEO. Payling has also been appointed to the newly created position of chief operating officer. Former AusBiotech head Tony Coulepis has been appointed as a director.
Jane Wilder, former company secretary and corporate solicitor for Tempo Services, will replace Bernadette Kerrigan as Ventracor's (ASX:VCR) company secretary and legal counsel.
Anadi (ASX:ANX) has appointed part-time consultant to the company, Arie Nudel, as a director.
Perth-based GM mouse supplier Ozgene has entered into a license agreement with French company Cellectis to use its patent for creating, developing and selling mice relating to mouse knock-ins.
GlaxoSmithKline's anti-thrombotic drug Arixtra has been approved by the European Commission for use in surgical patients at high risk of life-threatening venous blood clots. This follows US FDA approval of the same indication in May. Arixtra is a synthetic form of the natural anti-clotting agent heparin, and Brisbane biopharma Alchemia (ASX:ACL) has an identical, generic molecule ready for launch when GSK's five-year market exclusivity expires next year.
More effective antibiotic found for Lyme disease
Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...
Why do our waistlines expand in middle age?
A new preclinical study highlights the importance of controlling new fat-cell formation to...
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
